Overexpression of BRCA2 gene in sporadic breast tumours

被引:65
作者
Bièche, I
Noguès, C
Lidereau, R
机构
[1] Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France
[2] Ctr Rene Huguenin, Dept Stat Med, F-92211 St Cloud, France
[3] Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France
关键词
breast carcinoma; BRCA2; quantitative RT-PCR;
D O I
10.1038/sj.onc.1202903
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The breast cancer susceptibility gene BRCA2 is expressed in a wide range of tissues as an Il-lib mRNA transcript that encodes a 3418-amino acid protein involved in the response to DNA damage. To obtain better a molecular characterization of BRCA2 expression in sporadic breast cancer, we quantified BRCA2 mRNA by means of RT- PCR in a large series of human primary breast tumours, BRCA2 expression showed wide variations in tumour tissues, being underexpressed in 14/127 (11%) and overexpressed in 25/127 (20%), BRCA2 overexpression (but not underexpression) correlated significantly with Scarff, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours, BRCA2 status (under and/or overexpression versus normal expression) was not associated with subsequent relapse and with significantly shorter disease-free survival. The observed disruption of BRCA2 expression is not due to allelic loss, because the latter did not correlate with altered BRCA2 mRNA expression in our tumour series. Taken together, these data suggest the involvement, especially by overexpression, of the BRCA2 gene in sporadic breast tumours, and the existence of another important tumour-suppressor gene in breast cancer, in the 13q12-q13 region.
引用
收藏
页码:5232 / 5238
页数:7
相关论文
共 37 条
[1]   Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer [J].
Beckmann, MW ;
Picard, F ;
An, HX ;
vanRoeyen, CRC ;
Dominik, SI ;
Mosny, DS ;
Schnurch, HG ;
Bender, HG ;
Niederacher, D .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1220-1226
[2]   Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma [J].
Bieche, I ;
Nogues, C ;
Rivoilan, S ;
Khodja, A ;
Latil, A ;
Lidereau, R .
BRITISH JOURNAL OF CANCER, 1997, 76 (11) :1416-1418
[3]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[4]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[5]   LOSS OF HETEROZYGOSITY IN SPORADIC BREAST-TUMORS AT THE BRCA2 LOCUS ON CHROMOSOME 13Q12-Q13 [J].
CLETONJANSEN, AM ;
COLLINS, N ;
LAKHANI, SR ;
WEISSENBACH, J ;
DEVILEE, P ;
CORNELISSE, CJ ;
STRATTON, MR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1241-1244
[6]   Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers [J].
Collins, N ;
Wooster, R ;
Stratton, MR .
BRITISH JOURNAL OF CANCER, 1997, 76 (09) :1150-1156
[7]  
COLLINS N, 1995, ONCOGENE, V10, P1673
[8]   BRCA2 germline mutations in male breast cancer cases and breast cancer families [J].
Couch, FJ ;
Farid, LM ;
DeShano, ML ;
Tavtigian, SV ;
Calzone, K ;
Campeau, L ;
Peng, Y ;
Bogden, B ;
Chen, Q ;
Neuhausen, S ;
ShattuckEidens, D ;
Godwin, AK ;
Daly, M ;
Radford, DM ;
Sedlacek, S ;
Rommens, J ;
Simard, J ;
Garber, J ;
Merajver, S ;
Weber, BL .
NATURE GENETICS, 1996, 13 (01) :123-125
[9]   HUMAN BETA-ACTIN RETROPSEUDOGENES INTERFERE WITH RT-PCR [J].
DIRNHOFER, S ;
BERGER, C ;
UNTERGASSER, G ;
GELEY, S ;
BERGER, P .
TRENDS IN GENETICS, 1995, 11 (10) :380-381
[10]   QUANTITATION OF RNA USING THE POLYMERASE CHAIN-REACTION [J].
FOLEY, KP ;
LEONARD, MW ;
ENGEL, JD .
TRENDS IN GENETICS, 1993, 9 (11) :380-385